Big Rock Partners Acquisition Corp. (BRPA) to Combine with NeuroRx
Big Rock Partners Acquisition Corp. (NASDAQ:BRPA) announced this morning that it has entered into a merger agreement with biopharmaceutical firm NeuroRx that would give it an equity value of about $500 million. NeuroRx is working to develop two drugs – RLF-100 which could potentially serve as a treatment for COVID-19 symptoms, and NRX-101, which aimsRead More
To access this post, you must purchase 1 - User: Monthly Plan.